The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)

Diabetes After Total Pancreatectomy Clinical Trial

Official title: The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion

Status Completed

Clinical Trial Summary

The overall objective of this study is to investigate whether hypoglycaemia (the most potent stimulus of pancreatic glucagon secretion) affects the secretion of gut-derived glucagon in totally pancreatectomized patients.

Clinical Trial Description

The investigators want to assess the plasma glucagon response to insulin-induced hypoglycaemia in totally pancreatectomised patients and at the same time evaluate whether hypoglycaemia affects a range of other products from endocrine cells in the gastrointestinal tract including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic polypeptide (GIP), GLP-1, glucagon-like peptide-2 (GLP-2), oxyntomodulin and peptide YY (PYY). Furthermore the investigators will evaluate how hypoglycaemia in these patients affects other counter-regulatory mechanisms including plasma responses of the hormones adrenaline, noradrenaline, growth hormone and cortisol as well as the rate of gastric emptying rate (which under normal circumstances accelerates during hypoglycaemia) during an oral glucose tolerance test (OGTT). ;

Related Conditions & MeSH terms

• Diabetes After Total Pancreatectomy
• Hypoglycemia

• NCT number: NCT04064203
• Study type: Interventional
• Source: University Hospital, Gentofte, Copenhagen
• Status: Completed
• Phase: N/A
• Start date: July 5, 2017
• Completion date: September 20, 2018